Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - hepatitis b immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - hepatitis b immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle-stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals: - household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. - common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. - institutional contacts. - staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals: - household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. - common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. - insstitutional contacts. - staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor xiii, quantity: 62.5 iu/ml - injection, diluent for - excipient ingredients: water for injections - fibrogammin is indicated for adult and paediatric patients ? for prophylactic treatment of congenital fxiii deficiency and ? for peri-operative management of surgical bleeding with congenital fxiii deficiency. fibrogammin is furthermore indicated ? for haemorrhagic diatheses caused completely or in part by acquired fxiii deficiency ? for supportive therapy in case of disturbance in wound healing, especially in ulcus cruris, after large surgery or injuries.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - fibrinogen -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - c1 esterase inhibitor -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii,von willebrand factor -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii,von willebrand factor -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1000 iu; factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor fviii deficiency due to haemophilia a.